Richard Briscoe

Richard Briscoe has a strong background in safety assessment and research operations. Richard is currently serving as the Senior Vice President of Safety Assessment and Research Operations at Cerevel Therapeutics since August 2022. Prior to this, they held the position of Vice President of Safety Assessment at the same company from July 2019 to August 2022.

Before joining Cerevel Therapeutics, Briscoe worked at Merck for a significant period. Richard served as the Safety Assessment Therapeutic Area Lead for the Neuroscience and Ophthalmology Franchise from November 2010 to June 2019. Richard also held the roles of Director in the Strategy Development Group from April 2009 to November 2010, and Director of Pre-Clinical Safety Assessment from December 2002 to April 2009.

Earlier in their career, Briscoe worked as the Director of Safety Pharmacology at MPI Research from 1999 to 2002. Prior to that, they served as a Research Fellow in the Department of Pharmacology at the University of Michigan from 1997 to 1999.

Richard Briscoe received a Bachelor of Science degree in Psychology/Biology from Central Michigan University from 1988 to 1991. Later, they pursued their Ph.D. at the University of Oklahoma Health Sciences Center, completing the degree in 1997. The field of study for their Ph.D. is not specified.